Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

• Status: Withdrawn
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if dynamic hyperinflation seen in patients with idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: American Medical Association Foundation
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• 18 years of age or greater.

• Idiopathic Pulmonary Arterial Hypertension, or Familial Pulmonary Arterial Hypertension.

• Forced expiratory flow 75% (FEF75%) of ≤ 65% of predicted.

Exclusion Criteria:

• Clinical instability or change in medication therapy in preceding 3 months.

• Allergy or intolerance to inhaled albuterol.

• Body mass index > 30

• Active tobacco use, or > 10 pack-year smoking history.

• Lung disease other than pulmonary hypertension

• Forced expiratory volume in 1 second (FEV1) ≤ 80% of predicted.

• Pregnancy

• Inability to perform pulmonary function testing.

• Inability to perform cardiopulmonary exercise testing.

• Supplemental oxygen requirement.

• Inability to read and understand English.

• Historical 6-minute walk distance <150 meters